Shelley Miyamoto

Dr. Shelley Miyamoto


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
SMShelley Miyamoto
Shelley Miyamoto
AKAnis Karimpour-Fard
Anis Karimpour-Fard
VPValencia Peterson
Valencia Peterson
SAScott R. Auerbach
Scott R. Auerbach
KSKurt R. Stenmark
Kurt R. Stenmark
Carmen C. SucharovCarmen C. Sucharov
Carmen C. Sucharov

1 April 2017 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
KWKathleen C. Woulfe
Kathleen C. Woulfe
ASAustine K. Siomos
Austine K. Siomos
HNHieu Nguyen
Hieu Nguyen
MSMegan SooHoo
Megan SooHoo
CGCsaba Galambos
Csaba Galambos
SMShelley Miyamoto
Shelley Miyamoto

1 January 2015 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
Carmen C. SucharovCarmen C. Sucharov
Carmen C. Sucharov
JSJuliana Sucharov
Juliana Sucharov
AKAnis Karimpour-Fard
Anis Karimpour-Fard
KNKarin Nunley
Karin Nunley
BSBrian Stauffer
Brian Stauffer
SMShelley Miyamoto
Shelley Miyamoto

20 December 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
AVAngela Velleca
Angela Velleca
MSMichael A Shullo
Michael A Shullo
KDKumud Dhital
Kumud Dhital
EAEstela Azeka
Estela Azeka
MCMonica Colvin
Monica Colvin
ZRZdenka Reinhardt
Zdenka Reinhardt

1 August 2014 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
SMShelley Miyamoto
Shelley Miyamoto
BSBrian Stauffer
Brian Stauffer
JPJeremy Polk
Jeremy Polk
AMAllen Medway
Allen Medway
MFMatthew Friedrich
Matthew Friedrich
Carmen C. SucharovCarmen C. Sucharov
Carmen C. Sucharov

1 September 2018 in Circulation: Heart Failure
Verified
Journal Article
Closed access
Anastacia Marie GarciaAnastacia Marie Garcia
Anastacia Marie Garcia
SNStephanie J. Nakano
Stephanie J. Nakano
AKAnis Karimpour-Fard
Anis Karimpour-Fard
KNKarin Nunley
Karin Nunley
PBPenny Blain-Nelson
Penny Blain-Nelson
SMShelley Miyamoto
Shelley Miyamoto
Background: Single ventricle (SV) congenital heart disease is fatal without intervention, and eventual heart failure is a major cause of morbidity and mortality. Although there are no proven medical therapies for the treatment or prevention of heart failure in the SV heart disease population, phosphodiesterase-5 inhibitors (PDE5i), such as sildenafil, are increasingly used. Although the pulmonary vasculature is the primary target of PDE5i therapy in patients with SV heart disease, the effects of PDE5i on the SV heart disease myocardium remain largely unknown. We sought to determine PDE5 expression and activity in the single right ventricle of SV heart disease patients relative to nonfailing controls and to determine whether PDE5 impacts cardiomyocyte remodeling using a novel serum-based in vitro model. Methods and Results: PDE5 expression (n=9 nonfailing; n=7 SV heart disease), activity (n=8 nonfailing; n=9 SV heart disease), and localization (n=3 SV heart disease) were determined in explanted human right ventricle myocardium. PDE5 is expressed in SV heart disease cardiomyocytes, and PDE5 protein expression and activity are increased in SV heart disease right ventricle compared with nonfailing right ventricle. Isolated neonatal rat ventricular myocytes were treated for 72 hours with nonfailing or SV heart disease patient serum±sildenafil. Reverse transcription quantitative polymerase chain reaction (n=5 nonfailing; n=12 SV heart disease) and RNA sequencing (n=3 nonfailing; n=3 SV heart disease) were performed on serum-treated neonatal rat ventricular myocytes and demonstrated that treatment with SV heart disease sera results in pathological gene expression changes that are attenuated with PDE5i. Conclusions: PDE5 is increased in failing SV heart disease myocardium, and pathological gene expression changes in SV heart disease serum-treated neonatal rat ventricular myocytes are abrogated by PDE5i. These results suggest that PDE5 represents an intriguing myocardial therapeutic target in this population.